The impact of ivermectin-loaded solid lipid nanoparticles on the enteric phase of experimental trichinellosis.

Trichinellosis is a global zoonotic disease affecting humans and nearly all animal species. The intestinal (enteric) phase of trichinellosis is critical, as it determines the course and prognosis of the disease. The medications used in the management of trichinellosis demonstrate inadequate bioavailability, along with a significant level of resistance. Therefore, there is a need for the development of novel agents that enhance the bioavailability of administered medications. Nanobiotechnology has emerged as a significant strategy in treating parasitic diseases. This study examined the use of solid lipid nanoparticles (SLNs) to improve the efficacy of oral ivermectin (IVM) in treating the enteric phase of trichinellosis. Thirty-five Swiss albino mice were divided into seven equal groups as follows: negative control, positive control, albendazole, ivermectin, SLNs, ivermectin loaded on solid lipid nanoparticles (IVM-SLNs), and a combination of IVM-SLNs and albendazole. Mice were sacrificed on the seventh day post-infection. The drugs' effects were assessed using parasitological, biochemical, histological, histochemical and immunohistochemical analyses. The co-administration of albendazole and IVM-SLNs resulted in a significant decrease in adult burden, inflammatory cell infiltration, and apoptosis. Furthermore, a significant reduction in Cyclooxygenase-2 (COX-2) expression was observed compared to the infected untreated control group, along with improved liver and kidney function indices. In conclusion, the potent trichinocidal effect of a single oral dose of IVM-SLNs against Trichinella adults makes them a promising alternative or adjunct to existing nematicidal agents.